Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors

Journal of Immunology

Volumn 184, Issue 10, 2010, Pages 5895-5902

  Merlo, Anna ^a   Turrini, Riccardo ^a   Bobisse, Sara ^a   Zamarchi, Rita ^b   Alaggio, Rita ^a   Dolcetti, Riccardo ^c   Mautner, Josef ^d   Zanovello, Paola ^a,b   Amadori, Alberto ^a,b   Rosato, Antonio ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; EPITOPE; HLA ANTIGEN CLASS 1; HLA DR ANTIGEN;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; B CELL LYMPHOMA; BIOSYNTHESIS; CELL LINE; CYTOTOXICITY TEST; DOWN REGULATION; EPSTEIN BARR VIRUS INFECTION; IMMUNOLOGY; MARMOSET; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; PATHOLOGY; SECRETION; TRANSPLANTATION; TUMOR CELL LINE; VIROLOGY;

ANIMALS; CALLITHRIX; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOWN-REGULATION; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, B-CELL; MICE; MICE, SCID;

EID: 77954722311     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902850     Document Type: Article

References (53)

1. Hochberg, D., J. M. Middeldorp, M. Catalina, J. L. Sullivan, K. Luzuriaga, and D. A. Thorley-Lawson. 2004. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc. Natl. Acad. Sci. USA 101: 239-244.
2. Küppers, R. 2003. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat. Rev. Immunol. 3: 801-812.
3. Young, L. S., and A. B. Rickinson. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4: 757-768.
4. Rooney, C. M., C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9-13.
5. Haque, T., G. M. Wilkie, M. M. Jones, C. D. Higgins, G. Urquhart, P. Wingate, D. Burns, K. McAulay, M. Turner, C. Bellamy, et al. 2007. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131.
6. Rickinson, A. B., and D. J. Moss. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15: 405-431.
7. Straathof, K. C., C. M. Bollard, U. Popat, M. H. Huls, T. Lopez, M. C. Morriss, M. V. Gresik, A. P. Gee, H. V. Russell, M. K. Brenner, et al. 2005. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus - specific T lymphocytes. Blood 105: 1898-1904.
8. Comoli, P., P. Pedrazzoli, R. Maccario, S. Basso, O. Carminati, M. Labirio, R. Schiavo, S. Secondino, C. Frasson, C. Perotti, et al. 2005. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23: 8942-8949.
9. + Hodgkin's disease. J. Exp. Med. 200: 1623-1633.
10. Münz, C. 2004. Epstein-Barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target. J. Exp. Med. 199: 1301-1304.
11. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7: 791-802.
12. + T-helper 1 responses. J. Virol. 75: 8649-8659.
13. + T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood 109: 1138-1146.
14. + T lymphocytes: a critical component of antitumor immunity. Cancer Invest. 23: 413-419.
15. + T cell-dependent tumor rejection in the anterior chamber of the eye. J. Immunol. 171: 2789-2796.
16. + T cells without induction of phthisis. J. Immunol. 167: 5832-5837.
17. + cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood 99: 3302-3309.
18. + T cells: ready for direct attack. J. Exp. Med. 203: 805-808.
19. + CTLs ex vivo. J. Immunol. 168: 5954-5958.
20. Moosmann, A., N. Khan, M. Cobbold, C. Zentz, H. J. Delecluse, G. Hollweck, A. D. Hislop, N. W. Blake, D. Croom-Carter, B. Wollenberg, et al. 2002. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood 100: 1755-1764. (Pubitemid 34925154)
21. Rosato, A., G. Milan, D. Collavo, and P. Zanovello. 1999. DNA-based vaccination against tumors expressing the P1A antigen. Methods 19: 187-190. (Pubitemid 29497769)
22. + T cells by using virus-like particles. J. Virol. 82: 3903-3911.
23. + T cell preparations for therapy. PLoS ONE 2: e583.
24. + cytotoxic T lymphocytes in humans. Blood 95: 2352-2355.
25. Lacerda, J. F., M. Ladanyi, D. C. Louie, J. M. Fernandez, E. B. Papadopoulos, and R. J. O'Reilly. 1996. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. J. Exp. Med. 183: 1215-1228.
26. Keyaerts, M., J. Verschueren, T. J. Bos, L. O. Tchouate-Gainkam, C. Peleman, K. Breckpot, C. Vanhove, V. Caveliers, A. Bossuyt, and T. Lahoutte. 2008. Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur. J. Nucl. Med. Mol. Imaging 35: 999-1007.
27. Jaffe, E. S., N. L. Harris, H. Stein, and J. W. Vardiman. 2001. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In WHO Classification of Tumours, Vol. 3. World Health Organization, Geneva, Switzerland, p. 351.
28. Wilkie, G. M., C. Taylor, M. M. Jones, D. M. Burns, M. Turner, D. Kilpatrick, P. L. Amlot, D. H. Crawford, and T. Haque. 2004. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J. Immunother. 27: 309-316.
29. Gattinoni, L., D. J. Powell, Jr., S. A. Rosenberg, and N. P. Restifo. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6: 383-393.
30. + T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol. 77: 12088-12104.
31. Kataoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. Yonehara, and K. Nagai. 1996. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156: 3678-3686.
32. + CTL and NK cells. Am. J. Transplant. 8: 627-636.
33. + T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells. J. Virol. 81: 4766-4775.
34. Long, H. M., J. Zuo, A. M. Leese, N. H. Gudgeon, H. Jia, G. S. Taylor, and A. B. Rickinson. 2009. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virustransformed B cells. Blood 114: 807-815.
35. Yuan, J., E. Cahir-McFarland, B. Zhao, and E. Kieff. 2006. Virus and cell RNAs expressed during Epstein-Barr virus replication. J. Virol. 80: 2548-2565. (Pubitemid 43271560)
36. + T helper cells. Eur. J. Immunol. 34: 2500-2509.
37. Hollenbaugh, J. A., and R. W. Dutton. 2006. IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J. Immunol. 177: 3004-3011.
38. Misko, I. S., T. B. Sculley, C. Schmidt, D. J. Moss, T. Soszynski, and K. Burman. 1991. Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component. Cell. Immunol. 132: 295-307.
39. Wright, K. L., and J. P. Ting. 2006. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 27: 405-412. (Pubitemid 44216195)
40. De Lerma Barbaro, A., A. De Ambrosis, B. Banelli, G. Li Pira, O. Aresu, M. Romani, S. Ferrini, and R. S. Accolla. 2008. Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-γ in promyelocytic cells. Int. Immunol. 20: 1457-1466.
41. Meissner, M., T. L. Whiteside, P. van Kuik-Romein, E. M. Valesky, P. J. van den Elsen, R. Kaufmann, and B. Seliger. 2008. Loss of interferon-γ inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation. Br. J. Dermatol. 158: 930-940.
42. Yee, C. 2006. Adoptive T-cell therapy of cancer. Hematol. Oncol. Clin. North Am. 20: 711-733.
43. Finn, O. J. 2008. Cancer immunology. N. Engl. J. Med. 358: 2704-2715.
44. van de Berg, P. J., E. M. van Leeuwen, I. J. ten Berge, and R. van Lier. 2008. Cytotoxic human CD4+ T cells. Curr. Opin. Immunol. 20: 339-343.
45. + T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J. Virol. 79: 4896-4907.
46. Muranski, P., A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, et al. 2008. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.
47. + T cells against NY-ESO-1. N. Engl. J. Med. 358: 2698-2703.
48. Altomonte, M., E. Fonsatti, A. Visintin, and M. Maio. 2003. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene 22: 6564-6569.
49. Rimsza, L. M., R. A. Roberts, T. P. Miller, J. M. Unger, M. LeBlanc, R. M. Braziel, D. D. Weisenberger, W. C. Chan, H. K. Muller-Hermelink, E. S. Jaffe, et al. 2004. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103: 4251-4258.
50. Diepstra, A., G. W. van Imhoff, H. E. Karim-Kos, A. van den Berg, G. J. te Meerman, M. Niens, I. M. Nolte, E. Bastiaannet, M. Schaapveld, E. Vellenga, and S. Poppema. 2007. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J. Clin. Oncol. 25: 3101-3108.
51. + T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J. Immunol. 181: 431-439.
52. + T-helper cells. Cancer Res. 62: 2600-2605.
53. McAulay, K. A., T. Haque, G. Urquhart, C. Bellamy, D. Guiretti, and D. H. Crawford. 2009. Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease. J. Immunol. 182: 3892-3901.